目的 观察脑栓通胶囊联合注射用尤瑞克林治疗急性脑梗死的临床疗效。方法 选取南阳市第二人民医院2015年1月-2018年12月收治的急性脑梗死患者150例，随机分为对照组和治疗组，每组各75例。对照静脉滴注注射用尤瑞克林，0.15 PNA单位溶于50 mL或100 mL生理盐水中，静滴30 min，1次/d；治疗组患者在对照组治疗基础上口服脑栓通胶囊，3粒/次，3次/d。两组患者均治疗2周。观察两组患者临床疗效，同时比较治疗前后两组患者内皮素-1（ET-1）、N末端B型钠尿肽原（NT-proBNP）、肿瘤坏死因子-α（TNF-α）水平及临床症状改善情况。结果 治疗后，对照组和治疗组临床有效率分别为81.33%和92.00%，两组比较差异有统计学意义（P<0.05）。治疗后，两组患者ET-1、NT-proBNP、TNF-α水平均显著下降（P<0.05），且治疗组患者ET-1、NT-proBNP、TNF-α水平显著低于对照组（P<0.05）。治疗后，两组患者NIHSS评分显著降低（P<0.05），且治疗组患者NIHSS评分显著低于对照组（P<0.05）。结论 脑栓通胶囊联合注射用尤瑞克林治疗急性脑梗死，能有效改善患者的临床症状，具有一定的临床推广应用价值。

Objective To observe the clinical effect of Naoshuantong Capsules combined with uriklin in treatment of acute cerebral infarction. Methods Patients (150 cases) with acute cerebral infarction in Nanyang Second People's Hospital from January 2015 to January 2018 were randomly divided into control and treatment groups, and each group had 75 cases. Patients in the control group were iv administered with Urinary Kallidinogenase for injection, 0.15 PNA dissolved into normal saline 50 mL or 100 mL, and dripped for 30 min, once daily. Patients in the treatment group were po administered with Naoshuantong Capsules on the basis of the control group, 3 grains/time, three times daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacy was evaluated, the ET-1, NT-proBNP, and TNF-α levels and the improvement of clinical symptoms in two groups before and after treatment were compared. Results After treatment, the clinical efficacy and in the control and treatment groups was 81.33% and 92.00%, respectively, and there were differences between two groups (P<0.05). After treatment, the ET-1, NT-proBNP, and TNF-α levels in two groups were significantly decreased (P<0.05), and which in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, the NIHSS scores in two groups were significantly decreased (P<0.05), and the scores in the treatment group were significantly lower than those in the control group (P<0.05). Conclusion Naoshuantong Capsules combined with uriklin in treatment of acute cerebral infarction can improve the symptoms, which has a certain clinical application value.

R971